TickerFactsScreenerDevelopers

Coherus Oncology, Inc. (CHRS) — Capital Expenditures

Annual figures by fiscal year, from SEC filings.

2012: $1.78M2013: $373.0K2014: $2.85M2015: $6.16M2016: $6.51M2017: $4.57M2018: $789.0K2019: $1.82M2020: $7.23M2021: $1.29M2022: $2.04M2023: $286.0K$286.0K
2012Capital Expenditures (USD)2023
Fiscal YearCapital ExpendituresChange YoY
2023$286.0K-86.0%
2022$2.04M+58.2%
2021$1.29M-82.2%
2020$7.23M+296.9%
2019$1.82M+130.9%
2018$789.0K-82.7%
2017$4.57M-29.8%
2016$6.51M+5.7%
2015$6.16M+116.4%
2014$2.85M+663.8%
2013$373.0K-79.1%
2012$1.78M—